Cancer drugs in India belong to a biochemical category of drugs that can be used to prevent, stop or treat cancer by attacking the malignant cells. Different categories of cancer medications include chemotherapy, immunotherapy, targeted therapy, hormone therapy, and palliative care medications. Chemotherapy kills cancer cells or stops their growth through cytotoxic agents. Chemotherapy can be immunomodulatory, allowing the body to increase its immune response to the cancer-targeting agent—immunotherapy; The methods lead to unique specific markers or pathways molecularly important for the survival of cancer cells; Therefore, precision medicine is more specific. Hormonal therapy for hormone-sensitive cancers works entirely through hormone action.
Cancer treatment becomes very cheap and accessible with generic and brand product formulations prepared by Indian pharmaceutical industries for cancer treatment. By being biologically identical to the reference drug product, biologics will present an emerging cost advantage. Some of the major drugs include doxorubicin, trastuzumab, imatinib, paclitaxel, and pembrolizumab. Ayurvedic or other complementary treatments also help the patient, when used as an adjunct in conjunction with mainstream medicine.
Government programs and private sector collaboration, including the National Cancer Control Programme, worked hard to accommodate the timelines of cancer treatment processing facilities and then expand access to drugs deemed essential for treatment. However, issues such as high cost of treatment for poorly advanced medicine and inequality in access to care in rural areas remain. All this amidst ongoing research and reform of the national health sector, which will further strengthen cancer care delivery for India in the future.
1. Pembrolizumab
Another example of a revolutionary drug for immunotherapy, this apparently magical drug uses the immune system to treat cancer in a very surprising way. Following its approval in the US by the FDA in 2016, several surprising implications were announced. Working by targeting the immune checkpoint receptor on T-cells, it affects the PD-1 protein. When PD-1 binds with its ligands (PD-L1 and PD-L2), a situation such as down regulation of immune responses against the body's own cells occurs to prevent autoimmunity. But when used in this way, cancer cells hide themselves from the immune system. It blocks PD-1 and thereby reactivates T-cells to see and eliminate tumor cells.
The drug has proven effective in patients with advanced non-small cell lung cancer (NSCLC), melanoma, Hodgkin lymphoma, head and neck squamous cell carcinoma (HNSCC), and some gastric and cervical cancers. Furthermore, in metastatic HNSCC, clinical studies have demonstrated significantly increased survival rates compared with standard chemotherapy. Like every other medicine, pembrolizumab is also not without adverse effects. Common complaints include headache, skin rashes, arthralgia and myalgia; As well as hematological problems which often result in a decrease in the number of blood cells. Serious side effects may occur through immune-related adverse effects such as colitis or pneumonitis, which require very close monitoring during treatment. Today the price barrier is too high for most patients, especially in countries like India, where a 100 mg injection costs more than around ₹1,97,250. But it certainly leaves its mark in the field of oncological care as it potentially enhances survival and quality of life in advanced cancer patients.2. Drug Nivolumab
Nivolumab, another surprise treatment, is an immunomimetic agent that acts through inhibition of the PD-1 protein. In 2014 the U.S. Clinically approved by the FDA, it follows the same pathway as pembrolizumab, restoring the immune system's fingerprinting and malignancy-killing abilities. With binding against PD-1, immune cell activation is prevented, as cancer cells escape immune surveillance. So far, this drug has proven effective for many types of cancers: in the categories of Hodgkin and non-Hodgkin lymphoma, melanoma, cervical cancer, testicular cancer, squamous cell carcinoma, etc. It is known to increase survival rates during trials in patients with advanced melanoma, renal cell carcinoma, and NSCLC. Nivolumab is a drug that has proven to be very beneficial in the majority of cases; However, its use may cause some side effects to patients. It can induce fatigue, skin conditions and joint pain. Immune-related adverse reactions, such as colitis, hepatitis, and endocrine complications, may occur in severe cases and require intensive treatment. Nivolumab is a drug sold in India under the name Opdyta, with prices ranging from ₹39,800 for a 40 mg dose to ₹99,500 for a 100 mg dose. Although this drug is expensive, it is one of the most important treatments for cancer, especially in patients whose disease is advanced or refractory and, therefore, have limited options available.3. Trastuzumab
Monoclonal antibody Trastuzumab is a humanized monoclonal antibody that was approved in 1998 for diseases such as HER2-positive cancer. A protein that is overexpressed in breast and gastric cancers and promotes aggressive tumor growth, HER2, is downregulated by trastuzumab in terms of HER2 receptor binding as it blocks its signaling and leads to cancer cell destruction. Recruits immune cells in the direction of. Through clinical studies such as the landmark Hannah trial, safety as well as long-term efficacy was demonstrated. For patients suffering from early-stage HER2-positive breast cancer, treatment with trastuzumab achieved survival rates of more than 84%, emphasizing its importance in oncology. In addition to positive effects, trastuzumab also has side effects. These include mild infections, insomnia and respiratory problems. Serious side effects include cardiotoxicity, which requires monitoring at baseline and continuous cardiac monitoring during treatment. In India, trastuzumab is available as both Hervicta and Vivitra brands, with prices ranging between ₹6,500 to ₹39,496 depending on the prescribed dose. Due to its cost-effectiveness and efficacy, trastuzumab is a leading treatment modality in HER2-positive cancers.
4. Osimertinib
Osimertinib is another oral therapy approved by the FDA in 2018 for NSCLC with specific EGFR mutations. The receptor, EGFR, is involved in cell proliferation and commonly causes uncontrolled cell growth in lung cancer. Osimertinib is selected to inhibit only the mutated forms of EGFR and thus inhibit tumor growth while reducing the risk of recurrence. This drug is very effective in stage IV NSCLC for which adjuvant therapy has been used after surgery. In advanced-stage NSCLC, clinical trials have yielded response rates of up to 59%, making it a very promising entry into the field of targeted cancer therapy. However, osimertinib has its own side effects. These include the risk of anemia, mouth ulcers, and low blood counts. Although well tolerated in most cases, treatment requires proper monitoring of these adverse effects for best results. In India, osimertinib is sold under the brand name Tagrisso, which costs ₹1,50,154 for a 40 mg tablet. Although it has a high cost, it is remarkably effective for patients with EGFR-mutated NSCLC.5. Atezolizumab
Atezolizumab is a monoclonal antibody that targets PD-L1 and has been approved for use since 2016. PD-L1 is commonly used by tumors to suppress immune responses that promote uncontrolled growth. Atezolizumab inhibits PD-L1 and enforces T-cell function restoration leading to the immune system's ability to fight cancer. It is used to treat urothelial carcinoma, liver cancer, NSCLC and small cell lung cancer (SCLC). Studies have shown improved survival rates in NSCLC patients receiving atezolizumab compared to conventional treatments, making it an important option in advanced cancer treatment. Common side effects reported by patients include fatigue, nausea, and respiratory problems. In India, patients can get atezolizumab in the form of Tecentrix, which is priced between ₹2,77,708 to ₹3,96,725. Given its effectiveness and widespread use it is an important and routine agent in immunotherapy.6. Ipilimumab
Ipilimumab, approved in 2011, works by targeting CTLA-4, a checkpoint protein that suppresses T-cell activation. Inhibition of CTLA-4 results in an amplified immune response, most notably against aggressively advanced melanoma and some lung and kidney cancers. The efficacy of the above drug in combination with nivolumab is also evidenced by several clinical trials, including CheckMate-743, which shows that the use of both increases survival rates. However, it has been associated with some immune-related adverse events, such as diarrhea, fatigue, and skin rashes outside the pocket, for which close monitoring of patients is advised. It comes under the name Yervoi, and a 50 mg injection costs ₹72,500 in India. Regardless of that amount, it is one of the mainstays in the treatment of advanced stage cancer.
7. Bevacizumab
Bevacizumab is an anti-angiogenic agent against VEGF approved in 2004. It inhibits tumor angiogenesis which allows the tumor to develop vascular revascularization for food intake. Bevacizumab protects tumors from metabolism, starving them, thereby slowing their growth. It works for colorectal, breast, lung, kidney and cervical cancer. Common side effects include high blood pressure, fatigue, and blood clotting. In India, bevacizumab is available as Avastin and Bevatas, with prices ranging from ₹13,516 to ₹55,005.
8. Ribociclib
Ribociclib, a CDK4/6 inhibitor approved in 2017, inhibits cell division in hormone receptor-positive, HER2-negative breast cancer. Studies such as MONALEESA-2 demonstrate significant extension of progression-free survival. Adverse effects include fatigue, nausea, and baldness. In India, it is marketed under the Cryxana brand, at a quoted cost of ₹23,625. Its role in combination therapy has made ribociclib a cornerstone of advanced breast cancer management.
9. Sunitinib
Approved in 2006, sunitinib is a tyrosine kinase inhibitor of all pathways important for tumor growth and spread. For kidney cancer, GIST and pancreatic neuroendocrine tumors, it is used as a treatment. Common side effects are fatigue, skin problems, and nausea. In India, sunitinib is commercially available under the names Sunixar and Suticaine, with prices ranging from ₹386 to ₹1,850 per capsule.
10. Ibrutinib
Approved in 2013, ibrutinib inhibits Bruton tyrosine kinase (BTK), which is important for B-cell malignancies. This medicine treats patients with chronic lymphocytic leukemia, mantle cell lymphoma, and small lymphocytic lymphoma. Side effects such as pneumonia, muscle pain, and rashes with excessive bleeding may be experienced. In India, Ibrutinib is sold as Ibrunate and Nitib and is priced around ₹9,500-10,670 per capsule. This gives physicians a very effective option for the management of B-cell malignancies.
